{"denomUnitsSelected":"Participants","description":"Confirmed response will be evaluated in patients who crossover from single agent nivolumab to dual agent treatment following progression.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years","title":"Confirmed Response in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression","type":"OTHER_PRE_SPECIFIED"}